1. Introduction {#sec1-ijerph-16-03277}
===============

The Vietnamese Government estimates the number of people who inject drugs (PWIDs) in the country to be around 271,000 \[[@B1-ijerph-16-03277]\], of which 85% are heroin users. This population has been regarded as the key at-risk population for HIV infection in Vietnam, with HIV prevalence reported to be at 14%, higher than that of other at-risk populations such as sex workers (3.7%) and men who have sex with men (12.2%) \[[@B2-ijerph-16-03277]\]. Another report indicated that PWIDs accounted for 60% of newly HIV-infected cases in Vietnam \[[@B3-ijerph-16-03277]\]. Thus, interventions targeting this group would benefit the fight against the HIV/AIDS epidemic in the country. Among such interventions, while buprenorphine has been recently piloted for its feasibility and cost-effectiveness, methadone maintenance treatment (MMT) has been found to be one of the most cost-effective methods to evidently reduce the use of opioids among those enrolled in the program in a number of countries globally \[[@B4-ijerph-16-03277],[@B5-ijerph-16-03277],[@B6-ijerph-16-03277],[@B7-ijerph-16-03277],[@B8-ijerph-16-03277]\]. The Government of Vietnam piloted the program in Hai Phong and Ho Chi Minh in 2008 \[[@B9-ijerph-16-03277]\] and has been scaling up nationwide after the success of the pilot \[[@B5-ijerph-16-03277]\]. By March 2017, 51,318 drug users had been provided MMT by 280 methadone clinics in 63 cities and all provinces of Vietnam \[[@B8-ijerph-16-03277]\].

Polysubstance use or substance use disorder is a general term for a combination of several drugs for therapeutic or alternative purposes over a period of time \[[@B10-ijerph-16-03277]\]. It is widely acknowledged that the use multiple substances have increased recently \[[@B10-ijerph-16-03277]\]. Previous works have reported that the combination of opioids, for example, heroin with benzodiazepine, raises the levels of toxicity and overdose death \[[@B11-ijerph-16-03277]\]. In Vietnam, heroin has been known as the most commonly used drug, with the proportion of drug users using heroin ranging from 65% to 85% \[[@B12-ijerph-16-03277],[@B13-ijerph-16-03277]\]. Heroin users have reported that they consumed heroin concurrently with other drugs, including crystal methamphetamine (15%), marijuana (7.0%), and amphetamines (2.8%) \[[@B14-ijerph-16-03277]\]. The combination of different drugs might be attributed to the purpose of increasing excitement, which is highly enjoyed by drug users \[[@B15-ijerph-16-03277]\].

In a similar vein, research has shown that concurrent use of other substances is not uncommon among patients registering for MMT programs \[[@B16-ijerph-16-03277],[@B17-ijerph-16-03277],[@B18-ijerph-16-03277]\]. A study of 434 patients in Ukraine receiving opioid agonist treatment found that 23% reported concurrent drug use in the previous 30 days \[[@B19-ijerph-16-03277]\]. In 53 stabilized patients undergoing MMT in Italy, almost 60% concurrently used cocaine, alcohol, or both \[[@B20-ijerph-16-03277]\]. Among 103 patients undergoing MMT in New York, USA, 40% used cocaine, 43% used alcohol, 19% used sedatives, 3% used hallucinogens, and 32% had used cannabis in the previous 30 days \[[@B21-ijerph-16-03277]\]. In Vietnam, a previous study revealed that while there were only 14.4% of patients testing positive for heroin urine samples \[[@B22-ijerph-16-03277]\], the prevalence of smoking and frequent alcohol drinking among MMT patients was 87.3% and 29.6%, respectively \[[@B23-ijerph-16-03277]\]. Another study on MMT in mountainous areas found the prevalence of concurrent opioid use to be 13.4% \[[@B24-ijerph-16-03277]\]. Hazardous alcohol consumption, smoking, and use of other substances have been found to have a significant impact on the long-term efficacy of MMT \[[@B25-ijerph-16-03277]\].

Many factors believed to be involved in the concurrent use of opioids in MMT patients have been elucidated. Age of onset of opioid abuse \[[@B26-ijerph-16-03277]\], frequency of opioid use \[[@B27-ijerph-16-03277]\], peer pressure \[[@B27-ijerph-16-03277],[@B28-ijerph-16-03277]\], living with family members who use heroin \[[@B29-ijerph-16-03277]\], and concomitant antiretroviral and tuberculosis treatment \[[@B27-ijerph-16-03277]\] have all been found to be positive predictors of concurrent opioid use in MMT patients.

In this study, we sought to contribute to the abundant MMT literature by examining polysubstance uses, which included both illicit drugs and drinking/smoking, in a pool of participants attending public and private MMT clinics in Nam Dinh, Vietnam, one of the areas with the highest number of opioid users. The inclusion of a private clinic is significant, as it is the first fully functioning private MMT clinic in Vietnam and has the potential to shoulder the burden of public clinics in providing MMT services in an era of shrinking foreign aid for programs to combat HIV/AIDS and drug use. In addition, as the prevalence of substance use as well as its determinants vary depending on specific settings, more contextualized factors should be thoroughly examined in order to develop robust interventions for improving the quality of care to and health of MMT patients.

2. Materials and Methods {#sec2-ijerph-16-03277}
========================

2.1. Study Design and Participants {#sec2dot1-ijerph-16-03277}
----------------------------------

From January to September 2018, we conducted a cross-sectional study in Nam Dinh Province. Nam Dinh is one of the largest settings offering care services for HIV/AIDS in the north of Vietnam. The study settings were three outpatient clinics, including the Giao Thuy district health center, the Dai Dong private health facility, and the Giao Thuy Center for Social Evils Prevention. These three clinics all have at least two years of experience in providing MMT services and are in accordance with the official guidelines of the Ministry of Health of Vietnam.

Take-all sampling in the private health center and convenience sampling in the two public health centers were applied to recruit respondents for the study. All the respondents who met the inclusion criteria were invited to enroll to our study \[[@B30-ijerph-16-03277]\]. The inclusion criteria for respondents were (1) aged at least 18 years, (2) using MMT services from clinics mentioned above, and (3) willing to participate in the study by signing the informed consent form. Participants who suffered from serious illnesses or did not have the capacity to answer questions from data collectors were excluded from the recruitment process. A total of 395 participants agreed to participate in the study. The percentage of patients in each health facility who participated in the study was 100% (Dai Dong private health facility), 70.4% (Giao Thuy district health center), and 47.2% (Giao Thuy Center for Social Evils Prevention).

2.2. Measure and Instruments {#sec2dot2-ijerph-16-03277}
----------------------------

Twenty-minute face-to-face interviews were conducted in a small counseling room to ensure privacy and confidentiality. Before answering the questionnaire, informed consent was obtained. The interviewers were well-trained researchers. Health staff from the MMT study settings were not invited to the interviews to avoid social desirability bias. Our research members invited participants to join the study when they received medication or counseling services. Eligible participants were defined based on feedback from the medical staff. A pilot survey was carried out among 20 participants of different ages, genders, and occupations. A structured questionnaire was developed to obtain the following information:Socioeconomic characteristics

Participants self-reported their information about age, education, marital status, occupation, and monthly family income. MMT-service-related characteristics

Participants' time of MMT treatment was self-reported, and current MMT dose was extracted from the medical report. Participants self-reported their MMT adherence using a Likert scale (five options from "Very good" to "Very bad"). In addition, a 100-point visual analog scale (VAS) was applied to rate their adherence, with the score ranging from 0 "completely nonadherent" to 100 "completely adherent". The patient was classified as optimal adherence if he assessed his MMT adherence at 100 points, and 0--99 points was defined as suboptimal. Health risk behavior

Participants self-reported their frequency of drinking alcohol and smoking tobacco. Regarding drug use, date of initially using drugs, whether they inject drugs, and currently using drugs or not were also examined. If they answered "Yes" to the question on current use, we asked them about the frequency, the main reasons for continuous drug use, and the amount of money spent on drugs. Based on alcohol, tobacco, and drug usage, we divided the sample into three levels of polysubstance use groups: none, using one substance, using two or more types of substances.

2.3. Statistical Analysis {#sec2dot3-ijerph-16-03277}
-------------------------

STATA version 12 (Stata Corp. LP, College Station, United States of America) was used for data analysis. Chi-squared and Kruskal--Wallis tests were used for analyzing the demographic characteristics of the participants as well as MMT-related characteristics and health risk behaviors. We also used multivariate logistic regression to find associated factors with alcohol, tobacco, and illicit drug usage. Multivariate Poisson regression was used to find factors related to polysubstance use status. A forward stepwise selection strategy with a threshold of 0.2 was applied to remove insignificant factors. A *p*-value of \<0.05 was considered as statistically significant.

2.4. Ethical Approval {#sec2dot4-ijerph-16-03277}
---------------------

The study protocol was reviewed and granted ethics approval by the Institutional Review Board of the National Institute of Hygiene and Epidemiology (code: 726/QDVSDTTU).

3. Results {#sec3-ijerph-16-03277}
==========

[Table 1](#ijerph-16-03277-t001){ref-type="table"} describes the socioeconomic information of the participants in this study. The majority of participants had a secondary school education or above (83.3%). More than two-thirds of the respondents lived with a spouse/partner (77%). About one-third of the participants were self-employed (35.2%), followed by blue-collar workers/farmers (23.3%), and the proportion of unemployed participants was only about 10%. The percentage of participants having an average financial condition was the highest (76%), and the proportion of the five groups of quintile monthly family income was approximately equal (approximately 20%). The mean age was 40 (SD = 8.9), and there was no statistical difference between the three groups of polysubstance use.

Methadone-treatment-related characteristics among patients are presented in [Table 2](#ijerph-16-03277-t002){ref-type="table"}. The mean MMT duration was 3.3 years (SD = 2.2), and the mean of the current MMT dose was 69.2 mg (SD = 37). The proportion of participants receiving MMT treatment at a private facility was nearly similar to those being treated in a public facility (49.4% and 50.6%, respectively). Approximately two-thirds of participants reported a history of injecting drug (63.8%). Approximately half of the patients reported optimal MMT adherence (43.3%), and there was no statistical difference between the three study groups.

[Table 3](#ijerph-16-03277-t003){ref-type="table"} illustrates the substance use patterns among MMT patients. In terms of the frequency of alcohol drinking, half of the participants had never drunk alcohol (46.6%), and about one-fourth of the participants drank alcohol every day (24.8%). More than two-thirds of respondents smoked on a regular basis (68.6%). Only 6% of MMT patients used illicit drugs (5.8%), and among them, 78.3% used them once per week. Craving was the reason for maintaining drug use for six patients (21.6%). Peer pressure was considered as the main reason for maintaining drug use (47.8%).

[Table 4](#ijerph-16-03277-t004){ref-type="table"} shows the factors that were associated with different types of substance abuse. In terms of alcohol drinking, participants who lived with a spouse/partner (OR = 2.01; 95% CI = 1.05--3.86) and were self-employed (OR = 2.33; 95% CI = 1.01--5.39) were more likely to drink alcohol. Smoking was a factor increasing the likelihood of drinking alcohol (OR = 3.06; 95% CI = 1.73--5.43), and participants drinking alcohol were more likely to smoke tobacco (OR = 3.11; 95% CI = 1.77--5.46). Compared with optimal adherence, MMT suboptimal adherence was associated with a higher likelihood of illicit drug usage (OR = 24.24; 95% CI = 3.1--189.8) as well as polysubstance use (Coef = 0.12; 95% CI = 0.01--0.22).

4. Discussion {#sec4-ijerph-16-03277}
=============

This study enriches the current literature about the pattern of substance use among MMT patients in the developing country of Vietnam. In this study, we found a substantially high prevalence of polysubstance use in MMT patients. Moreover, the polysubstance use in our patients was driven by some critical factors such as medication adherence and service delivery models.

Our finding indicates that tobacco is the most common (81%) substance used among patients participating in the MMT program. This result is in line with previous reports which also found an extremely high level of cigarette use (the prevalence varies between 77% and 88%) in MMT patients \[[@B29-ijerph-16-03277],[@B31-ijerph-16-03277]\]. Among middle-income countries, Vietnam has a high level of cigarette consumption \[[@B27-ijerph-16-03277]\]. It is evident that nicotine binds to the nicotine acetylcholine receptors in the central nervous system and stimulates dopamine release in the nucleus acumens, increasing euphoria and drug liking in smokers \[[@B32-ijerph-16-03277],[@B33-ijerph-16-03277]\]. The literature suggests that patients use nicotine to relieve withdrawal symptoms of heroin including depression, restlessness, and irritability \[[@B32-ijerph-16-03277],[@B34-ijerph-16-03277]\]. Besides, smoking is a leading cause of incidence in illicit drug users \[[@B35-ijerph-16-03277],[@B36-ijerph-16-03277]\]. However, there has been little research on smoking behavior as well as smoking cessation in this population in Vietnam. Further intervention should integrate the MMT program with smoking cessation services to control cigarette use among MMT patients.

The second most commonly used substance is alcohol (54%). Our result is comparable to a 2014 study of five MMT patients in Dehong Prefecture in Yunnan Province, China, which found that 58.6% of the sample reported current alcohol drinking \[[@B37-ijerph-16-03277]\]. However, a 2013 multisite (including both urban and rural areas) study of MMT patients found alcohol usage among patients to be at 29.6%, which is lower than the proportion of our sample \[[@B14-ijerph-16-03277]\]. A possible explanation could be that our patients' sample was taken from an urban area in Vietnam, which facilitates more convenient access to alcohol.

Only 6% of our patients reported the use of illicit drugs, which included heroin, amphetamine, ecstasy, morphine, and methamphetamine. Craving was the second most reported reason for maintaining drug use (26.1%), and drug craving can be lowered by adjusting methadone doses. Moreover, patients with suboptimal MMT adherence were more likely to have concurrent illicit drug use. This finding is consistent with similar relationships observed in MMT patients in other countries \[[@B38-ijerph-16-03277],[@B39-ijerph-16-03277]\]. We suggest that to increase the efficacy of MMT, treatment adherence by MMT patients can be closely monitored, which would require healthcare workers to provide personalized support to each patient. Peer pressure was the most commonly cited reason for illicit drug use, which is consistent with a study in another MMT patient group in Vietnam \[[@B28-ijerph-16-03277]\]. Thus, it is important for policymakers to initiate community-based education in combination with social and family support to help methadone patients reduce illicit drug consumption.

Also, we found that patients receiving treatment in a public facility were associated with a lower likelihood of using alcohol and polysubstance use. The field of private healthcare service in Vietnam is nascent and was only formally recognized just over 20 years ago. The scale of private healthcare services is small compared with the public sector, and in general, information about its services is limited \[[@B40-ijerph-16-03277]\]. As of the time of this writing, the quality of private healthcare services is also poorly regulated, resulting in a large variance in the quality of healthcare delivery compared with the more centralized model of delivery of public healthcare \[[@B40-ijerph-16-03277]\]. Since MMT remains a new field in the healthcare system, there is only one private health clinic presently providing MMT (Dai Dong private health clinic) in northern Vietnam \[[@B41-ijerph-16-03277]\]. After the policies enacted in 2012 for provincial budgets, copayment by patients in all HIV-related services has been required to reduce the financial burden \[[@B42-ijerph-16-03277]\]. It is suggested that this user fee not only pay for the methadone drug but also be used as a means of domestic resources \[[@B43-ijerph-16-03277]\]. Based on our findings, we recommend that the government provide its support and expertise in helping the private health sector establish an efficient and effective MMT program.

There were further interesting findings regarding factors associated with alcohol use in our MMT patients. Firstly, patients who live with their partner or spouse were more likely to use alcohol compared with those who live alone. We postulate that this could be due to family and peer influence, which is a strongly associated factor in substance use \[[@B29-ijerph-16-03277]\]. Concerning this, future health strategies could target patients' family and social circle when psycho-educating and counseling them about the risks of substance usage. Secondly, self-employed patients were more likely to engage in alcohol usage compared with those who were unemployed. There could be a cultural explanation for this finding. In Vietnam, alcohol drinking has become a sociocultural norm, especially when connecting with colleagues and business clients for those who are employed \[[@B44-ijerph-16-03277]\]. Thirdly, smokers were more likely to drink alcohol, and vice versa (OR = 3.06; 3.11). This association was not surprising, as many studies have shown that both tobacco and alcohol abuse are often comorbid among MMT patients \[[@B17-ijerph-16-03277],[@B18-ijerph-16-03277],[@B45-ijerph-16-03277]\]. Both substances serve to decrease anxiety and depression symptoms (albeit temporarily, for as long as the substance is still in the blood) \[[@B46-ijerph-16-03277],[@B47-ijerph-16-03277],[@B48-ijerph-16-03277]\] commonly experienced in opioid withdrawal. The importance of implementing a robust MMT program with a strong emphasis on patients' adherence cannot be understated, as optimal adherence to MMT can prevent opioid withdrawal symptoms such as anxiety and malaise \[[@B8-ijerph-16-03277]\].

To the best of our knowledge, this is the first study investigating the pattern of polysubstance use in Vietnamese MMT patients. Our study provides a basis for further research to build on our findings and expand the understanding of factors driving the behavior of polysubstance use in Vietnamese MMT patients. There are several limitations to this study. As this is a cross-sectional study, causality relationships cannot be drawn among the various factors that we studied. Further research should address this with a longitudinal study design. Convenience sampling was used, and this could lead to a sample which may not be representative of the population. Moreover, the self-reported nature of the questionnaire potentially makes the results subject to response bias and providing inaccurate data \[[@B49-ijerph-16-03277]\]. While MMT clinics conduct urine tests for patients on MMT, periodically or unexpectedly, this study did not collect data on urine drug tests for cross-validation with the self-reported data. In addition, future works on the topic of polysubstance use disorder may benefit from looking into the possible use of benzodiazepine among the sampled cohort, as benzodiazepine abuse has been found to be an issue for MMT patients in the United States due to inability of methadone to block benzodiazepine's effects. The engagement of MMT patients in smoking and drinking can also be further assessed by exploring the quantity consumed instead of just frequency of use, as in our study. Furthermore, information on dropouts among study participants as well as the drop-out history of the respondents is recommended to be included in future studies to provide a comprehensive picture of MMT adherence.

5. Conclusions {#sec5-ijerph-16-03277}
==============

In conclusion, we found that tobacco and alcohol are the most common substances used by MMT patients in Vietnam. The importance of the implementation of a robust MMT program with a strong emphasis on patients' adherence cannot be understated, as we found that optimal adherence to MMT was associated with reduced illicit substance use. Furthermore, a community-based educational and support program on substance use could be launched to effectively target the significant effect of peer pressure on substance use. Finally, future research should further analyze the pattern of polysubstance usage among MMT patients in a longitudinal study to gain better insights into how to develop a more effective MMT program among people who inject drugs.
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ijerph-16-03277-t001_Table 1

###### 

Demographic characteristics of participants.

  Characteristics                      Polysubstance Use   Total    *p*-Value                                                    
  ------------------------------------ ------------------- -------- ----------- -------- ---------- -------- ---------- -------- ---------------
  **Total**                            48                  12.2     153         38.7     194        49.1     395        100.0    
  **Education**                                                                                                                  
    Under secondary school             8                   16.7     26          17.0     32         16.5     66         16.7     0.09 \*
    Secondary school                   23                  47.9     101         66.0     113        58.3     237        60.0     
    Above secondary school             17                  35.4     26          17.0     49         25.3     92         23.3     
  **Marital status**                                                                                                             
    Single                             11                  22.9     28          18.3     28         14.4     67         17.0     0.64 \*
    Living with partner/spouse         34                  70.8     115         75.2     155        79.9     304        77.0     
    Divorced/widowed                   3                   6.3      10          6.5      11         5.7      24         6.1      
  **Occupation**                                                                                                                 
    Unemployed                         7                   14.6     13          8.5      13         6.7      33         8.4      0.04 \*
    Self-employed                      18                  37.5     47          30.7     74         38.1     139        35.2     
    Blue-collar worker/farmer          14                  29.2     36          23.5     42         21.7     92         23.3     
    Business                           6                   12.5     11          7.2      11         5.7      28         7.1      
    Other                              3                   6.3      46          30.1     54         27.8     103        26.1     
  **Family financial condition**                                                                                                 
    Wealthy                            0                   0.0      2           1.3      9          4.6      11         2.8      0.16 \*
    Average                            35                  72.9     116         75.8     149        76.8     300        76.0     
    Poor                               13                  27.1     35          22.9     36         18.6     84         21.3     
  **Quintile monthly family income**                                                                                             
    Poorest                            15                  31.3     32          20.9     33         17.0     80         20.3     0.31 \*
    Poor                               7                   14.6     36          23.5     39         20.1     82         20.8     
    Middle                             11                  22.9     26          17.0     44         22.7     81         20.5     
    Rich                               6                   12.5     35          22.9     41         21.1     82         20.8     
    Richest                            9                   18.8     24          15.7     37         19.1     70         17.7     
                                       **Mean**            **SD**   **Mean**    **SD**   **Mean**   **SD**   **Mean**   **SD**   ***p*-Value**
  **Age**                              39.9                10.2     39.8        8.8      40.1       8.6      40         8.9      0.96 ^\#^
  **Monthly family income** (USD)      434.3               640.7    434.3       593.4    425.7      464.4    430        537.5    0.53 ^\#^

\* Chi-squared test, ^\#^ Kruskal--Wallis test.

ijerph-16-03277-t002_Table 2

###### 

Methadone-treatment-related characteristics.

  Characteristics                Polysubstance Use   Total    *p*-Value                                                    
  ------------------------------ ------------------- -------- ----------- -------- ---------- -------- ---------- -------- ---------------
  **MMT model**                                                                                                            
  Private facility               18                  37.5     73          47.7     104        53.6     195        49.4     0.12 \*
  Public facility                30                  62.5     80          52.3     90         46.4     200        50.6     
  **Ever injected drugs**                                                                                                  
  Yes                            30                  62.5     95          62.1     127        65.5     252        63.8     0.79 \*
  No                             18                  37.5     58          37.9     67         34.5     143        36.2     
  **MMT adherence**                                                                                                        
  Optimal adherence              21                  43.8     73          47.7     77         39.7     171        43.3     0.33 \*
  Suboptimal adherence           27                  56.3     80          52.3     117        60.3     224        56.7     
                                 **Mean**            **SD**   **Mean**    **SD**   **Mean**   **SD**   **Mean**   **SD**   ***p*-Value**
  **MMT duration** (years)       3.4                 2.3      3.4         2.2      3.1        2.2      3.3        2.2      0.28 ^\#^
  **MMT dose** (mg)              65.7                36.9     73.8        38.9     66.4       35.2     69.2       37.0     0.05 ^\#^
  **Age at onset of drug use**   26.5                8.4      25.7        7.9      26         7.6      25.9       7.8      0.80 ^\#^

\* Chi-squared test, ^\#^ Kruskal--Wallis test. Abbreviation: MMT---methadone maintenance treatment.

ijerph-16-03277-t003_Table 3

###### 

Substance use patterns among MMT patients.

  Characteristics                                 *n*   \%
  ----------------------------------------------- ----- ------
  **Alcohol drinking frequency**                        
  None                                            184   46.6
  Once per week                                   72    18.2
  Every week                                      41    10.4
  Everyday                                        98    24.8
  **Smoking frequency**                                 
  None                                            75    19.0
  Once per week                                   20    5.1
  Every week                                      29    7.3
  Everyday                                        271   68.6
  **Concurrent illicit drug use**                 23    5.8
  **Frequency of concurrent drug use** (n = 23)         
  Once per week                                   18    78.3
  Every week                                      1     4.4
  Everyday                                        3     13.0
  More than once a day                            1     4.4
  **Reason for concurrent drug use** (n = 23)           
  Craving                                         6     26.1
  Habit                                           5     21.7
  Peer pressure influence                         11    47.8
  Other                                           1     4.4

ijerph-16-03277-t004_Table 4

###### 

Factors associated with different substance uses.

  Characteristics                                       n     \%      Alcohol Drinking   Smoking      Concurrent Illicit Drug Use   Polysubstance Use                                              
  ----------------------------------------------------- ----- ------- ------------------ ------------ ----------------------------- ------------------- -------------- -------------- ------------ --------------
  **Education**                                                                                                                                                                                    
  Less than secondary school                            66    16.7                                    Ref.                          \-                  Ref.           \-                          
  Secondary school                                      237   60.0                                    1.24                          0.60; 2.58          0.69           0.17; 2.86                  
  More than secondary                                   92    23.3                                    0.64                          0.28; 1.49          1.97           0.46; 8.44                  
  **Marital status**                                                                                                                                                                               
  Single                                                67    17.0    Ref.               \-                                                                                                        
  Living with partner/spouse                            304   77.0    2.01 \*\*          1.05; 3.86                                                                                                
  Divorced/widowed                                      24    6.1     0.99               0.35; 2.75                                                                                                
  **Occupation**                                                                                                                                                                                   
  Unemployed                                            33    8.4     Ref.               \-           Ref.                          \-                  Ref.           \-             Ref.         \-
  Self-employed                                         139   35.2    2.33 \*\*          1.01; 5.39   0.95                          0.38; 2.36          0.31           0.06; 1.59     0.13         −0.11; 0.37
  Blue-collar/farmer                                    92    23.3    1.33               0.56; 3.18   1.02                          0.40; 2.63          1.25           0.25; 6.25     0.10         −0.16; 0.35
  Business                                              28    7.1     0.59               0.19; 1.82   1.54                          0.45; 5.27          2.20           0.38; 12.77    −0.01        −0.36; 0.34
  Other                                                 103   26.1    1.42               0.59; 3.39   4.38 \*\*\*                   1.43; 13.42         0.88           0.19; 4.13     0.20         −0.04; 0.45
  **Quintile monthly family income**                                                                                                                                                               
  Poorest                                               80    20.3                                                                                                                    Ref.         \-
  Poor                                                  82    20.8                                                                                                                    0.12         −0.05; 0.29
  Middle                                                81    20.5                                                                                                                    0.14         −0.04; 0.32
  Rich                                                  82    20.8                                                                                                                    0.13         −0.03; 0.30
  Richest                                               70    17.7                                                                                                                    0.13         −0.06; 0.32
  **Age**                                               395   100.0   1.03 \*\*          1.00; 1.06   0.96 \*\*\*                   0.93; 0.99                                                     
  **MMT model**                                                                                                                                                                                    
  Private facility                                      195   49.4    Ref.               \-                                                             Ref.           \-             Ref.         \-
  Public facility                                       200   50.6    0.60 \*\*          0.39; 0.93                                                     0.39 \*        0.14; 1.06     −0.13 \*\*   −0.23; −0.02
  **Ever injected drugs**                                                                                                                                                                          
  No                                                    252   63.8    Ref.               \-                                                                                                        
  Yes                                                   143   36.2    1.36               0.86; 2.14                                                                                                
  **MMT adherence**                                                                                                                                                                                
  Optimal adherence                                     171   43.3    Ref.               \-                                                             Ref.           \-             Ref.         \-
  Suboptimal adherence                                  224   56.7    1.35               0.87; 2.10                                                     24.24 \*\*\*   3.10; 189.80   0.12 \*\*    0.01; 0.22
  **MMT dose** (mg)                                     395   100.0                                   1.00                          0.99; 1.00                                                     
  **Age at onset of drug use**                          395   100.0                                                                                     0.90 \*\*      0.82; 0.98                  
  **Alcohol drinking**                                                                                                                                                                             
  No                                                    184   46.6                                    Ref.                          \-                                                             
  Yes                                                   211   53.4                                    3.11 \*\*\*                   1.77; 5.46                                                     
  **Smoking**                                                                                                                                                                                      
  No                                                    75    19.0    Ref.               \-                                                             Ref.           \-                          
  Yes                                                   320   81.0    3.06 \*\*\*        1.73; 5.43                                                     3.22           0.64; 16.19                 
  \*\*\* *p* \< 0.01, \*\* *p* \< 0.05, \* *p* \< 0.1                                                                                                                                              

^1^ Odds ratio. ^2^ Confidence intervals.
